Shedding of soluble receptor for tumor necrosis factor alpha induced by M. leprae or LPS from human mononuclear cells. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Shedding of soluble receptor for tumor necrosis factor alpha induced by M. leprae or LPS from human mononuclear cells.

Nihon Hansenbyo Gakkai Zasshi. 1999 Nov;68(3):185-93. Unique Identifier : AIDSLINE MED/20124839
Santos DO; Lorre K; de Boer M; Van Heuverswyn H; Department of Cellular and Molecular Biology, University Federal; Fluminense, Niteroi, Brasil.

Abstract: Cell surface expression and release of the tumor necrosis factor receptor (TNFR type I) was analyzed after stimulation of peripheral blood mononuclear cells (PBMC) with Mycobacterium leprae (M. leprae) or lipopolysaccharide (LPS). A transient spontaneous expression of TNFR type I on the surface of PBMC was observed. Two hr after activation with LPS, a significant reduction of TNFR type I expression was detected: Release of TNFR type I by M. leprae or LPS-stimulated PBMC was evaluated with an enzyme-linked immunoabsorbent assay. This release occurred relatively later (20 to 40 hr) than the secretion of TNF alpha which reached high levels between 8 to 20 hr after activation. Thalidomide, a potent drug for the treatment of erythema nodosum leprosum episodes by inhibiting TNF alpha production, had no influence on the TNFR type I expression. Similar results were obtained with pentoxifylline. It is concluded that the release of TNFR type I by M. leprae or LPS-stimulated PBMC may counteract the pro-inflammatory activities of TNF alpha, by reducing the systemic toxicity of this cytokine in leprosy.

Keywords: JOURNAL ARTICLE Cells, Cultured Depression, Chemical Human Leukocytes, Mononuclear/*IMMUNOLOGY/METABOLISM Lipopolysaccharides/*IMMUNOLOGY Mycobacterium leprae/*IMMUNOLOGY Receptors, Tumor Necrosis Factor/*METABOLISM Support, Non-U.S. Gov't Thalidomide/PHARMACOLOGY Tumor Necrosis Factor/*METABOLISM

KWDjournalarticlecells,cultureddepression,chemicalhumanleukocytes,mononuclear/KWDimmunology/metabolismlipopolysaccharides/KWDimmunologymycobacteriumleprae/KWDimmunologyreceptors,tumornecrosisfactor/KWDmetabolismsupport,non-uKWDsKWDgov'tthalidomide/pharmacologytumornecrosisfactor/KWDmetabolism
000630
A0061969

Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .